SKU: C213

Size  
Quantity:
 
Price: make selection(s)
Description

2’-C-Methylcytidine (2CMC) is a viral replication inhibitor, shown to be active against multiple viruses including hepatitis C virus (HCV), inhibiting the HCV NS5B RNA polymerase.  It is also used against other viruses including Norwalk, West Nile, dengue, foot-and-mouth, and yellow fever.  It is sparingly soluble in water.

    CAS Number

    20724-73-6

    Molecular Formula

    C10H15N3O5

    Molecular Weight

    257.24

    Mechanism of Action

    2’-C-Methylcytidine has been shown to be a small-molecule inhibitor of viral nucleoside polymerase.  In hepatitis C virus, it inhibits HCV NS5B RNA polymerase.

    In studies with foot-and-mouth disease, experiments suggest that the compound interacts with the viral replication that coincides with the onset of intracellular viral RNA synthesis.

    Tariff Code

    2934.99.9001

    Spectrum

    Antiviral spectra includes Hepatitis C virus (HCV), Norwalk virus, pestivirus bovine viral diarrhea virus.  It is also effective for three flaviviruses including yellow fever virus, West Nile virus, and Dengue-2 virus.  It has in vitro activity against foot-and-mouth disease virus and yellow fever virus.

Applications

    Application

    2’-C-Methylcytidine is useful for the development of antiviral research compounds.

    Microbiology Applications

    NM 283 is an efficient prodrug of 2’-C-methylcytidine.  It is an 3’-O-L-valinyl ester derivative.  It is a promising antiviral for HCV infection (Pierra et al, 2011).

    Studies in a cell-based replicon assay indicated that several of the phosphoaramidates including NM283 demonstrated a 10- to 200-fold potency due to higher levels of 2’-C-methylcytidine triphosphate in the cells. These prodrugs are converted to the triphosphate in hepatocytes (Gardelli et al, 2009).

Specifications

    Form

    Powder

    Appearance

    off-white powder

References

    References

    Gardelli et al (2009)  Phosphoramidate prodrugs of 2’-C-methylcytidine for therapy of Hepatitis C virus infection. J. Med. Chem. 52(17):5394-5407  PMID 19725579

    Julander JG et al (2010)  Efficacy of 2’-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antivir. Res. 86(3):261-267  PMID 20227442

    Nesya G et al (2007)  2’-C-Methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 73(3):161-168  PMID 17055073

    Lee J et al (2015)  Characterization of the activity of 2’-C-methylcytidine against dengue virus replication. Antiviral Res. 116:1-9  PMID 25614455

    Pierra et al (2006)  Synthesis and pharmacokinetics of Valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2‘-C-methylcytidine. J. Med. Chem.  49(22):6614-6620  PMID 17064080

    Pierra C et al (2011)  NM 283, An efficient prodrug of the potent anti-HCV agent 2’-C-Methylcytidine. Nucleosides, Nucleotides and Nucl. Acids 24(5-7):767-770

    Rocha-Pereira JD et al (2013)  The viral polymerase inhibitor 2'-C-Methylcytidine inhibits Norwalk virus replication and protects against Norovirus-induced diarrhea and mortality in a mouse model. J. Virol.  87(21):11798-1805  PMID 23986582

Other Items In This Category